Literature DB >> 30291941

ASIC1a promotes high glucose and PDGF-induced hepatic stellate cell activation by inducing autophagy through CaMKKβ/ERK signaling pathway.

Yinghong Wang1, Yancai Sun1, Longquan Zuo2, Yanan Wang2, Yan Huang3.   

Abstract

It is well known that the diabetes mellitus complicates liver fibrosis with high morbidity, and Acid-sensing ion Channel 1a (ASIC1a) plays an important role in the development of diabetes and liver fibrosis. However, the underlying mechanism about how diabetes influences the progression of liver fibrosis remains unclear. This study was to investigate the relationship between autophagy and ASIC1a in the process of liver fibrosis under hyperglycemia. Interestingly, our study showed that the autophagy was elevated in the livers from diabetes combined with liver fibrosis double model in vivo and also in rat hepatic stellate cell line HSC-T6 after stimulation with high glucose and platelet-derived growth factor (PDGF) in vitro, and this response could be attenuated by treatment with ASIC1a nonspecific inhibitor Amiloride or specific ShRNA for ASIC1a. Furthermore, inhibition of autophagy treated with 3-MA significantly attenuated HSC-T6 activation and proliferation. Mechanistically, CaMKKβ/ERK pathway was activated in HSC-T6 after stimulation with high glucose and PDGF, and could be suppressed by Amiloride. Collectively, we concluded that autophagy induced by ASIC1a contributes to HSC-T6 activation, which ing pathway.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ASIC1a; Autophagy; HSCs; Hyperglycemia; Liver fibrosis

Mesh:

Substances:

Year:  2018        PMID: 30291941     DOI: 10.1016/j.toxlet.2018.10.003

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  8 in total

1.  Inonotsuoxide B suppresses hepatic stellate cell activation and proliferation via the PI3K/AKT and ERK1/2 pathway.

Authors:  Juan Jin; Hui Yang; Lili Hu; Yinghong Wang; Wenyong Wu; Chengmu Hu; Kun Wu; Zehua Wu; Wenming Cheng; Yan Huang
Journal:  Exp Ther Med       Date:  2022-04-28       Impact factor: 2.447

2.  ASIC1α up-regulates MMP-2/9 expression to enhance mobility and proliferation of liver cancer cells via the PI3K/AKT/mTOR pathway.

Authors:  Yinci Zhang; Jiaojiao Liang; Niandie Cao; Jiafeng Gao; Yinghai Xie; Shuping Zhou; Xiaolong Tang
Journal:  BMC Cancer       Date:  2022-07-16       Impact factor: 4.638

Review 3.  Self-eating: friend or foe? The emerging role of autophagy in fibrotic diseases.

Authors:  Yajing Li; Runping Liu; Jianzhi Wu; Xiaojiaoyang Li
Journal:  Theranostics       Date:  2020-06-29       Impact factor: 11.556

Review 4.  Autophagy and Exosomes: Cross-Regulated Pathways Playing Major Roles in Hepatic Stellate Cells Activation and Liver Fibrosis.

Authors:  Eleftheria M Mastoridou; Anna C Goussia; Georgios K Glantzounis; Panagiotis Kanavaros; Antonia V Charchanti
Journal:  Front Physiol       Date:  2022-02-03       Impact factor: 4.566

5.  ASIC1a promotes the proliferation of synovial fibroblasts via the ERK/MAPK pathway.

Authors:  Jingjing Tao; Zheng Lu; Jingwen Su; Xuewen Qian; Yihao Zhang; Yayun Xu; Sujing Song; Xiaoyu Hang; Xiaoqing Peng; Feihu Chen
Journal:  Lab Invest       Date:  2021-07-19       Impact factor: 5.502

Review 6.  The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  Int J Mol Sci       Date:  2020-05-29       Impact factor: 5.923

7.  The Phenylethanol Glycoside Liposome Inhibits PDGF-Induced HSC Activation via Regulation of the FAK/PI3K/Akt Signaling Pathway.

Authors:  Shi-Lei Zhang; Long Ma; Jun Zhao; Shu-Ping You; Xiao-Ting Ma; Xiao-Yan Ye; Tao Liu
Journal:  Molecules       Date:  2019-09-09       Impact factor: 4.411

8.  The angiotensin-converting enzyme inhibitor, captopril, suppressed hepatic stellate cell activation via NF-kappaB or wnt3α/β-catenin pathway.

Authors:  Zhaodi Gu; Linjun Fang; Peijun Ma
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.